Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product
Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product SOUTH SAN FRANCISCO, Calif.--- BUSINESS WIRE ---Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company’s first product
View HTML
Toggle Summary New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples South San Francisco, Calif.--- PRNewswire ---Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial
View HTML
Toggle Summary New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results
New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results South San Francisco, Calif. --- September 1, 2011 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today
View HTML
Toggle Summary Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis South San Francisco, Calif. --- January 9, 2012 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that
View HTML
Toggle Summary Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients Cambridge, Mass. and South San Francisco, Calif. --- January 20, 2012 --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world’s leading biotechnology companies,
View HTML
Toggle Summary Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director
Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director South San Francisco, Calif. --- April 5, 2012 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Richard T.
View HTML
Toggle Summary Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis
Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis Cambridge, Mass. and South San Francisco, Calif. --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY ), and Veracyte, Inc., a molecular diagnostics company
View HTML
Toggle Summary Veracyte Announces Study Results Published Online in New England Journal of Medicine Which Suggest that Its Afirma® Gene Expression Classifier Can Reduce Unnecessary Thyroid Surgeries
Findings Also Presented at ENDO 2012: The 94th Annual Meeting & Expo
View HTML
Toggle Summary New Study Suggests That Use of Veracyte’s Afirma® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results
New Study Suggests That Use of Veracyte’s Afirma® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results South San Francisco, Calif. and Cambridge, Mass. — July 17, 2012 — Veracyte, Inc.
View HTML
Toggle Summary Veracyte Receives New York State License for Afirma® Gene Expression Classifier
Veracyte and Genzyme Also Announce that Memorial Sloan-Kettering Cancer Center is Among the State’s First Institutions to Offer Genomic Test to Patients with Inconclusive Thyroid Nodule Results
View HTML